Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
Headache The Journal of Head and Face Pain2020Vol. 60(8), pp. 1734–1742
Citations Over TimeTop 10% of 2020 papers
Gary Berman, Robert Croop, David Kudrow, Philip Halverson, Meghan Lovegren, Alexandra Thiry, Charles M. Conway, Vladimir Coric, Richard B. Lipton
Abstract
Rimegepant, when used as an oral acute treatment in patients receiving CGRP mAbs as preventive treatment, was well tolerated; no safety issues were identified. Studies involving larger patient populations are needed to confirm these findings.
Related Papers
- → Is calcitonin gene-related peptide a reliable biochemical marker of migraine?(2022)23 cited
- → Plasma Calcitonin Gene-Related Peptide in Diagnosing and Predicting Paediatric Migraine(2009)53 cited
- → Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study(2015)7 cited
- → Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study(2017)4 cited
- → Migraine and the Scope of Homeopathy(2017)1 cited